Review Article
Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis
Table 1
Mechanisms of action of contemporary and emerging MS therapies.
| Drug | Mechanism of action |
| IFN-β and Glatiramer acetate | Inhibition of the induction and proliferation of autoreactive T cells | Fingolimod | Prevention of egress of CD4+ & CD8+ T cells, and B cells from secondary lymphoid tissues | Natalizumab | Blockade of transmigration of autoreactive T cells into the CNS | Rituximab | Depletion of B cells and attenuation of antibody independent proinflammatory B cell functions | Alemtuzumab | Depletion of CD4+ & CD8+ T cells, B cells, NK cells, and monocytes | Daclizumab | Expansion in CD56bright NK cells; inhibition of activated T-cell proliferation |
|
|